New hope for Tough-to-Treat breast cancer: trial tests Hormone-Blocking drug
NCT ID NCT07016399
Summary
This study is testing if adding a hormone-blocking drug called darolutamide to standard chemotherapy and immunotherapy before surgery works better for a specific type of early-stage, triple-negative breast cancer. About 51 patients with this cancer type will be randomly assigned to receive either the standard treatment or the standard treatment plus darolutamide. The main goal is to see if the new combination shrinks tumors more effectively and improves long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.